¶ FGL (FGLL): Benefits, Dosage, & Side Effects
| Sequence | Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-Lys-Ser-Lys-Ala |
| Short Seq | EVYVVAENQQGKSKA |
| Category | NCAM Mimetic / Nootropic |
| Origin | Synthetic (NCAM FN3 Module) |
| Admin | Intranasal, Subcutaneous |
| Status | Investigational / Research Chemical |
FGL (also known as FGLL or the Fibroblast Growth Loop peptide) is a synthetic peptide mimetic derived from the Neural Cell Adhesion Molecule (NCAM). It is designed to bind directly to and activate the Fibroblast Growth Factor Receptor (FGFR), a critical signaling hub for neuronal growth, survival, and synaptic plasticity.
Originally developed to treat neurodegenerative conditions like Alzheimer’s disease and stroke, FGL has demonstrated potent effects on memory retention and synaptic strengthening (Long-Term Potentiation) in animal models. While it successfully passed Phase I human safety trials demonstrating excellent tolerability, its clinical development has since stalled, leaving it as a prominent "orphan" compound in nootropic research.
¶ At a glance
Aliases
- FGL: Fibroblast Growth Loop
- FGLL: The dimeric form used in clinical trials (two FGL chains linked)
- NCAM-mimetic peptide: Refers to its origin from the NCAM protein
- Sequence: Glu-Val-Tyr-Val-Val-Ala-Glu-Asn-Gln-Gln-Gly-Lys-Ser-Lys-Ala
Key points
- Primary Benefit: Enhances synaptic plasticity and memory formation by mimicking the natural "growth" signal of NCAM.
- Mechanism: Directly activates the FGFR1 receptor, triggering downstream pathways (PKC, ERK) that strengthen synapses (LTP).
- Status: Experimental. It passed a Phase I human safety trial in 2007 but has not been approved for any medical use.
- Safety: Appeared safe in limited human testing (up to 200 mg intranasal), but long-term human safety data is non-existent.
What people use it for
- Nootropic: enhancing memory, learning speed, and cognitive retention.
- Neuroprotection: Investigated for recovery after stroke or traumatic brain injury.
- Mood: Preclinical evidence suggests antidepressant and anxiolytic properties.
- Evidence Quality: Low/Preclinical. Robust animal data exists, but human efficacy data is lacking.
¶ Legal & regulatory status
⚠️ CRITICAL INFORMATION
Regulatory classification
- FDA Status: Unapproved. FGL is an investigational compound that has not received FDA approval for any indication. It is legally classified as a research chemical.
- Prescription Requirement: Not available by prescription. It can only be sourced from research chemical suppliers for laboratory use.
- DEA Schedule: Not scheduled. It is not a controlled substance in the US.
Sports and competition
- WADA Status: Not explicitly listed, but could fall under the "Catch-all" category of non-approved substances (S0) or peptide hormones/growth factors (S2) depending on interpretation. Athletes should exercise extreme caution.
Source quality considerations
- Research Grade Only: Since there is no pharmaceutical product, all FGL on the market is "research grade." This implies no regulatory oversight on purity, sterility, or heavy metal content.
- Purity Risks: Third-party testing is essential to ensure the peptide sequence is correct and free from synthesis byproducts.
¶ What is FGL?
FGL is a 15-amino acid peptide derived from the Fibroblast Growth Factor Receptor (FGFR) binding site of the Neural Cell Adhesion Molecule (NCAM).
¶ The "Velcro" of the Brain
To understand FGL, you must understand NCAM. NCAM is a protein expressed on the surface of neurons that acts like "molecular Velcro." It helps neurons stick to each other and stabilizes synapses.
- Natural Function: When NCAM on one neuron binds to NCAM on another (or to receptors like FGFR), it signals the neuron to "strengthen this connection."
- The Problem: Using full NCAM proteins as a drug is impossible—they are too large and complex.
- The Solution (FGL): Scientists identified the exact 15-amino acid loop (the "FG loop") on NCAM that physically touches the FGFR receptor. By synthesizing just this loop, they created a small peptide that can "trick" the receptor into activating, without needing the giant protein attached.
¶ Development History
FGL was championed by Enkam Pharmaceuticals A/S (Denmark) in the early 2000s. It was developed as a treatment for Alzheimer’s disease and conditions of memory loss.
- Phase I Success: In 2007, a study published in Clinical Pharmacokinetics showed that intranasal FGL (FGLL) was safe in healthy men.
- Stalled Progress: Despite this success, Enkam Pharmaceuticals ceased operations (approx. 2012–2016), and no Phase II efficacy trials were published. The peptide remains a tool in academic neuroscience but has not advanced commercially.
¶ What are FGL's main benefits?
Note: The following benefits are primarily based on robust preclinical (animal) models. Human efficacy has not been established.
¶ 1. Memory and Cognitive Enhancement
The most well-documented effect of FGL is its ability to facilitate Long-Term Potentiation (LTP)—the cellular process that underlies memory formation.
- Spatial Memory: Rats treated with FGL learn to navigate mazes significantly faster and retain that information longer than controls[1].
- Social Memory: It prolongs the duration of social recognition memory in rodents, likely via oxytocinergic pathways[2].
- Age-Related Decline: In aged rats (equivalent to elderly humans), FGL treatment restored synaptic flexibility to levels seen in young animals, effectively reversing age-related cognitive stiffness[3].
¶ 2. Neuroprotection (Alzheimer's and Stroke)
FGL appears to protect neurons from stress and toxicity.
- Alzheimer's Models: In rats injected with amyloid-beta (the toxic protein in Alzheimer's), FGL prevented neuronal death and cognitive decline. It works by inhibiting GSK3β, a kinase that drives tau tangles and cell death[4].
- Stroke Recovery: In models of stroke (ischemia), FGL reduces the size of the brain injury and helps mobilize neural stem cells to repair damage[5].
¶ 3. Depression and Anxiety
There is evidence that FGL acts as a rapid-acting antidepressant and anxiolytic.
- Mechanism: NCAM-deficient mice show severe depression-like behavior. FGL reverses this, likely by boosting neurotrophic signaling (similar to how BDNF works in depression)[2:1].
¶ Evidence summary table
| Outcome / Goal | Effect | Consistency | Evidence quality | Trials | Notes |
|---|---|---|---|---|---|
| Safety & Tolerability | ✅ Safe | High | Moderate | 1 Phase I | Safe up to 200mg intranasal (single dose) in healthy men. |
| Memory Enhancement | High | Preclinical | >10 Animal | Robust effects on spatial/social memory in rats/mice. | |
| Synaptic Plasticity (LTP) | High | Preclinical | >15 In Vitro/In Vivo | Mechanistically proven to enhance LTP via FGFR1. | |
| Neuroprotection (AD/Stroke) | Moderate | Preclinical | ~5 Animal | Prevents amyloid toxicity and ischemic damage in rodents. | |
| Depression/Anxiety | Moderate | Preclinical | ~3 Animal | Reverses depressive behavior in NCAM-deficient models. |
- Evidence Quality Key:
- Moderate: Human safety data exists but is limited.
- Preclinical: Strong animal data, but no human efficacy trials confirmed.
¶ How does FGL work?
FGL is a "precision tool" for the FGFR1 receptor.
¶ Mechanism of Action
- Receptor Binding: FGL binds to the Fibroblast Growth Factor Receptor 1 (FGFR1) on the surface of neurons. It binds to a specific regulatory site that mimics the natural interaction with NCAM.
- Dimerization & Activation: This binding causes two FGFR1 receptors to pair up (dimerize) and activate.
- Signaling Cascade: Activation triggers phosphorylation of the receptor, launching three key pathways:
- PKC (Protein Kinase C): Critical for moving receptors to the synapse.
- MAPK/ERK: Drives gene expression for growth and plasticity.
- PI3K/Akt: Promotes cell survival (anti-apoptotic).
- Synaptic Strengthening: The ultimate result is the delivery of AMPA receptors to the synapse. More AMPA receptors mean the synapse is stronger and more sensitive to signals—this is the physical basis of Long-Term Potentiation (LTP)[1:1].
¶ Inhibition of GSK3β
FGL also leads to the phosphorylation (inactivation) of GSK3β.
- Why this matters: Overactive GSK3β is a villain in Alzheimer's; it creates tau tangles and kills neurons. By shutting it down, FGL protects the structural integrity of the neuron[4:1].
¶ Pharmacokinetics
- Half-life: Short in plasma (hours), but biological effects on synapses can last days due to downstream signaling changes.
- Bioavailability:
- Intranasal: Good. It bypasses the Blood-Brain Barrier (BBB) effectively, appearing in CSF and plasma within minutes.
- Subcutaneous: Also effective in animal models; crosses the BBB rapidly.
¶ Effects on different systems
¶ Brain & Mental Health
- Cognition: The primary target. Enhances acquisition (learning) and retention (memory).
- Mood: modulating the NCAM-FGFR pathway appears to have antidepressant effects, potentially by correcting deficits in neurogenesis or synaptic connectivity associated with depression.
¶ Immune Function & Inflammation
- Microglia Modulation: Recent research suggests FGL interacts with glial cells (the brain's immune cells). It upregulates CD200, a "peacekeeper" molecule that keeps microglia calm and prevents neuroinflammation. This is crucial because chronic brain inflammation drives aging and neurodegeneration.
¶ Administration and Storage
Note: Since FGL is an experimental chemical, these guidelines are derived from research literature and do not constitute medical advice.
¶ Routes of Administration
- Intranasal (Preferred for Nootropic Use)
- Why: Bypasses the blood-brain barrier and delivers peptide directly to the brain/olfactory nerves. Matches the route used in the successful human Phase I trial.
- Device: Nasal spray bottle.
- Subcutaneous Injection
- Why: Standard route in animal studies (neuroprotection).
- Site: Abdominal fat or thigh.
¶ Dosage Protocols
- Human Trial Dosage: The Phase I study tested single intranasal doses of 25 mg, 100 mg, and 200 mg[6].
- All doses were tolerated.
- Note: These are very high doses compared to potent modern peptides (like Semax), likely due to the need for high concentrations to drive receptor dimerization.
- Animal Equivalent: Rodent studies often use 10 mg/kg subcutaneous.
- Human equivalent estimate (approximate): ~1.6 mg/kg (e.g., ~110 mg for a 70kg person).
- Community "Bro-Science" Dosing: Anecdotal reports are rare for FGL. Due to the high cost of synthesis and the high doses required (milligrams vs micrograms), it is not a popular "everyday" nootropic.
¶ Reconstitution (for Injectable/Intranasal)
- Solvent: Bacteriostatic water or sterile saline.
- Handling: Fragile. Do not shake.
- Storage:
- Powder: -20°C (freezer).
- Reconstituted: 4°C (fridge). Use within 2-3 weeks.
¶ Safety and Side Effects
¶ Human Safety Data (Phase I)
In the only published human trial (Anand et al., 2007), FGL was administered intranasally to healthy men[6:1].
- Adverse Events: Mild and transient.
- Nasal irritation: Burning sensation or runny nose immediately after administration (likely due to the spray formulation).
- Systemic: No changes in heart rate, blood pressure, or ECG. No liver/kidney toxicity markers.
¶ Theoretical Risks
- Seizure Threshold: Because FGL facilitates excitation (LTP) and synaptic strengthening, there is a theoretical risk it could lower the seizure threshold in epileptics. However, animal studies showed it did not worsen seizures in kindled mice, though it made them develop slightly faster.
- Cancer: Since it activates FGFR (a growth factor receptor), there is a theoretical concern about promoting tumor growth. However, NCAM mimetics are generally considered distinct from broad-spectrum growth factors like HGH.
¶ Cost and Availability
- Availability: Very low. It is not commonly stocked by standard peptide vendors. It often requires custom synthesis.
- Cost: High. Because the effective dose is in the milligram range (e.g., 50-100mg) rather than microgram range, a single effective dose could cost significantly more than other nootropics like Semax or Noopept.
¶ References
Knafo, S., Venero, C., Sánchez-Puelles, C., Pereda-Peréz, I., Franco, A., et al. (2012). Facilitation of AMPA Receptor Synaptic Delivery as a Molecular Mechanism for Cognitive Enhancement. PLoS Biology, 10(2): e1001262. https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1001262 ↩︎ ↩︎
Turner, C. A., et al. (2019). Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates. Neuropsychopharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC6300554/ ↩︎ ↩︎
Popov, V. I., et al. (2008). A cell adhesion molecule mimetic, FGL peptide, induces alterations in synapse and dendritic spine structure in the dentate gyrus of aged rats: A three-dimensional ultrastructural study. European Journal of Neuroscience. https://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2008.06042.x ↩︎
Klementiev, B., et al. (2007). A synthetic peptide termed FGL derived from the neural cell adhesion molecule (NCAM) was able to prevent or, if already manifest, strongly reduce all investigated signs of Abeta25-35-induced neuropathology and cognitive impairment. Neuroscience. https://pubmed.ncbi.nlm.nih.gov/17223274/ ↩︎ ↩︎
Klein, R., et al. (2016). The Neural Cell Adhesion Molecule-Derived Peptide FGL Mobilizes Endogenous Neural Stem Cells, Promotes Remyelination and Modulates Neuroinflammation after Focal Ischemia. Journal of Neuroimmune Pharmacology. https://pubmed.ncbi.nlm.nih.gov/27352075/ ↩︎
Anand, R., Seiberling, M., Kamtchoua, T., & Pokorny, R. (2007). Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers. Clinical Pharmacokinetics, 46(4), 351–358. https://pubmed.ncbi.nlm.nih.gov/17375985/ ↩︎ ↩︎